Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Travere Therapeutics, Inc. TVTX
$15.82
-$0.33 (-2.10%)
На 18:04, 12 мая 2023
+76.99%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1243402193.00000000
-
week52high
29.14
-
week52low
14.51
-
Revenue
212018000
-
P/E TTM
-4
-
Beta
0.46124500
-
EPS
-4.86000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 08 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 26 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 06 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 окт 2022 г. |
| Piper Sandler | Overweight | Overweight | 14 окт 2022 г. |
| Piper Sandler | Overweight | Overweight | 11 янв 2023 г. |
| Stifel | Hold | 14 дек 2022 г. | |
| Wells Fargo | Overweight | 05 дек 2022 г. | |
| Canaccord Genuity | Buy | Buy | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Calvin Sandra | D | 42805 | 360 | 02 февр 2023 г. |
| REED ELIZABETH E | D | 57436 | 2590 | 01 февр 2023 г. |
| ROTE WILLIAM E. | D | 60036 | 2590 | 01 февр 2023 г. |
| Heerma Peter | D | 82069 | 1779 | 01 февр 2023 г. |
| Dube Eric M | D | 237150 | 8196 | 01 февр 2023 г. |
| Cline Christopher R. | D | 51533 | 1588 | 01 февр 2023 г. |
| Calvin Sandra | D | 43165 | 1671 | 01 февр 2023 г. |
| REED ELIZABETH E | D | 6750 | 6750 | 31 янв 2023 г. |
| REED ELIZABETH E | D | 54500 | 54500 | 31 янв 2023 г. |
| REED ELIZABETH E | A | 60026 | 20250 | 31 янв 2023 г. |
Новостная лента
Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is Critical
Seeking Alpha
26 янв 2023 г. в 12:05
Travere Therapeutics, Inc. is set to find out on Feb 17th whether the FDA has granted accelerated approval to lead drug candidate Sparsentan. Indicated for kidney disease IgAN and FSGS, the accelerated approval would be granted based on the drug's ability to reduce proteinuria.
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 16:30
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference, on Thursday, January 12, 2023, at 11:15 a.m. PT.
Travere Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire
09 ноя 2022 г. в 16:30
SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences:
Travere Therapeutics, Inc. (TVTX) Q3 2022 Earnings Call Transcript
Seeking Alpha
27 окт 2022 г. в 22:16
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2022 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President, Investor Relations Eric Dube - President and Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Senior Vice President of Research and Development Conference Call Participants Maurice Raycroft - Jefferies Greg Harrison - Bank of America Tim Lugo - William Blair Liisa Bayko - Evercore ISI Laura Chico - Wedbush Securities Ed Arce - H.C. Wainwright & Co. Operator Good day and welcome to the Travere Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call.
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
27 окт 2022 г. в 18:48
Travere (TVTX) delivered earnings and revenue surprises of -12.37% and 4.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?